Schiff Advises Underwriter in the Unicycive Therapeutics’ $25M IPO

News

Schiff Advises Underwriter in the Unicycive Therapeutics’ $25M IPO

News Release |

Schiff Hardin LLP acted as underwriter’s counsel for Unicycive Therapeutics’ $25 million initial public offering. Unicycive is a clinical stage biotechnology company developing therapies for patients with kidney disease. The offering closed July 15, 2021.

Roth Capital Partners is acting as the sole manager for the offering.